Following standard therapy for CF APE that included inpatient IV antibiotics and supportive care, IP-10 significantly and consistently decreased compared to pretreatment values (647 pg/mL [357, 1174], P<0.05, Figure 1B). The gene discussed is CXCL10; the disease is apparent mineralocorticoid excess.